Literature DB >> 6971697

[The pre-operative visit in cardiovascular surgery].

B Paiement, J G Maillé, M Boulanger, J Taillefer, P Sahab, C Pelletier, I Dyrda.   

Abstract

This text is intended for new residents in the development of anaesthesia of the Montreal Heart Institute. It presents a classification of the risk of cardiovascular surgery used in that institution and discusses current problems encountered with this type of patient (pulmonary and coagulation problems, diabetes renal failure). The attitudes of anaesthetists of this institution towards patients' medication and premedication are also discussed. The risk is classified as usual, increased or high, depending on the presence (or absence) of several factors known to increase the risk: ventricular dysfunction, heart failure, unstable angina or recent infarction, significant involvement of other systems (unstable diabetes, renal insufficiency, significant pulmonary dysfunction), age, emergency surgery and non-cardiac surgery in the presence of important cardiac pathology. With surgical procedures carrying a high mortality, for example dissecting thoracic aneurysm, the usual risk is high and is classified as such. A table of the usual risk of current surgical procedures is proposed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6971697     DOI: 10.1007/BF03006892

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  15 in total

1.  Clinical predictors of angina following myocardial infarction.

Authors:  D D Waters; P Theroux; C Halphen; H F Mizgala
Journal:  Am J Med       Date:  1979-06       Impact factor: 4.965

Review 2.  Nerve disease in diabetes mellitus.

Authors:  N Spritz
Journal:  Med Clin North Am       Date:  1978-07       Impact factor: 5.456

3.  Intubation and other experiences in cardiac surgery: the consumer's views.

Authors:  B Paiement; M Boulanger; C W Jones; M Roy
Journal:  Can Anaesth Soc J       Date:  1979-05

4.  The estimation of surgical risk.

Authors:  D W Feigal; F W Blaisdell
Journal:  Med Clin North Am       Date:  1979-11       Impact factor: 5.456

5.  Preoperative evaluation of the healthy patient.

Authors:  J A Robbins; A I Mushlin
Journal:  Med Clin North Am       Date:  1979-11       Impact factor: 5.456

6.  Surgery in the patient with renal disease and related electrolyte disorders.

Authors:  G R Burke; P F Gulyassy
Journal:  Med Clin North Am       Date:  1979-11       Impact factor: 5.456

7.  Practical application of the flow-volume loop.

Authors:  J A Golish; M Ahmad; J R Yarnal
Journal:  Cleve Clin Q       Date:  1980

8.  Right bundle-branch block and complete heart block caused by the Swan-Ganz catheter.

Authors:  I R Thomson; B C Dalton; D G Lappas; E Lowenstein
Journal:  Anesthesiology       Date:  1979-10       Impact factor: 7.892

9.  Determinants of mortality following coronary bypass surgery.

Authors:  C Pelletier; R Cossette; L Dontigny; C Mercier; A Pagé; A Verdant
Journal:  Can J Surg       Date:  1980-03       Impact factor: 2.089

10.  Preoperative endocrine and metabolic considerations.

Authors:  V A White; L F Kumagai
Journal:  Med Clin North Am       Date:  1979-11       Impact factor: 5.456

View more
  4 in total

1.  Arterial hypertension following coronary artery surgery: influence of the narcotic agent used for anaesthesia.

Authors:  J F Hardy; M Boulanger; J G Maillé; B Paiement; J Taillefer; P Sahab; M Delorme
Journal:  Can Anaesth Soc J       Date:  1983-07

2.  Hypertension following coronary artery bypass graft.

Authors:  W McIlvaine; M Boulanger; J G Maillé; B Paiement; J Taillefer; P Sahab
Journal:  Can Anaesth Soc J       Date:  1982-05

3.  A simple classification of the risk in cardiac surgery.

Authors:  B Paiement; C Pelletier; I Dyrda; J G Maillé; M Boulanger; J Taillefer; P Sahab; M Delorme; E Dupont
Journal:  Can Anaesth Soc J       Date:  1983-01

4.  A simple classification of the risk in cardiac surgery: the first decade.

Authors:  N A Tremblay; J F Hardy; J Perrault; M Carrier
Journal:  Can J Anaesth       Date:  1993-02       Impact factor: 5.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.